KARLA CALZADA MORALES: Open Payments
NPI 1013368349 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$699 in 32 payments from 10 companies in 2025. Trend: 2023 $50 · 2024 $747 · 2025 $699
Food & beverage: $699
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $120 |
| Alkermes, Inc. | 4 | $81 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Luye Pharma (USA) Ltd. | 2 | $47 |
| ABBVIE INC. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: COBENFY, CAPLYTA, INGREZZA, ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE, VRAYLAR.
Industry payments across FL — which companies pay providers there.
